Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina.
University of Alabama at Birmingham, Birmingham, AL, USA.
Int J Health Policy Manag. 2018 Feb 1;7(2):120-136. doi: 10.15171/ijhpm.2017.47.
The measurement of health benefits is a key issue in health economic evaluations. There is very scarce empirical literature exploring the differences of using quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) as benefit metrics and their potential impact in decision-making.
Two previously published models delivering outputs in QALYs, were adapted to estimate DALYs: a Markov model for human papilloma virus (HPV) vaccination, and a pneumococcal vaccination deterministic model (PNEUMO). Argentina, Chile, and the United Kingdom studies were used, where local EQ-5D social value weights were available to provide local QALY weights. A primary study with descriptive vignettes was done (n = 73) to obtain EQ-5D data for all health states included in both models. Several scenario analyses were carried-out to evaluate the relative importance of using different metrics (DALYS or QALYs) to estimate health benefits on these economic evaluations.
QALY gains were larger than DALYs avoided in all countries for HPV, leading to more favorable decisions using the former. With discounting and age-weighting - scenario with greatest differences in all countries - incremental DALYs avoided represented the 75%, 68%, and 43% of the QALYs gained in Argentina, Chile, and United Kingdom respectively. Differences using QALYs or DALYs were less consistent and sometimes in the opposite direction for PNEUMO. These differences, similar to other widely used assumptions, could directly influence decision-making using usual gross domestic products (GDPs) per capita per DALY or QALY thresholds.
We did not find evidence that contradicts current practice of many researchers and decision-makers of using QALYs or DALYs interchangeably. Differences attributed to the choice of metric could influence final decisions, but similarly to other frequently used assumptions.
健康效益的衡量是健康经济评估中的一个关键问题。几乎没有实证文献探讨使用质量调整生命年(QALYs)或伤残调整生命年(DALYs)作为效益指标的差异及其对决策的潜在影响。
我们对以前发表的两种输出为 QALYs 的模型进行了调整,以估计 DALYs:一种人乳头瘤病毒(HPV)疫苗接种的马尔可夫模型和一种肺炎球菌疫苗接种的确定性模型(PNEUMO)。使用了阿根廷、智利和英国的研究,这些研究提供了当地 EQ-5D 社会价值权重,以提供当地的 QALY 权重。进行了一项带有描述性情景的主要研究(n = 73),以获得两个模型中所有纳入健康状态的 EQ-5D 数据。进行了几种情景分析,以评估使用不同指标(DALYs 或 QALYs)来估计这些经济评估中的健康效益的相对重要性。
在所有国家,HPV 的 QALY 增益都大于 DALYs 避免,因此使用前者做出了更有利的决策。在所有国家中,考虑到折现和年龄加权——差异最大的情况——增量 DALYs 避免分别占阿根廷、智利和英国 QALY 增益的 75%、68%和 43%。对于 PNEUMO,使用 QALYs 或 DALYs 的差异不太一致,有时方向相反。这些差异与其他广泛使用的假设类似,可能会直接影响使用常见的人均国内生产总值(GDP)每 DALY 或 QALY 阈值的决策。
我们没有发现证据表明,目前许多研究人员和决策者将 QALYs 或 DALYs 互换使用的做法与实际情况不符。归因于指标选择的差异可能会影响最终决策,但与其他常用假设类似。